CA2837207A1 - Nouveaux modulateurs du systeme immunitaire - Google Patents

Nouveaux modulateurs du systeme immunitaire Download PDF

Info

Publication number
CA2837207A1
CA2837207A1 CA2837207A CA2837207A CA2837207A1 CA 2837207 A1 CA2837207 A1 CA 2837207A1 CA 2837207 A CA2837207 A CA 2837207A CA 2837207 A CA2837207 A CA 2837207A CA 2837207 A1 CA2837207 A1 CA 2837207A1
Authority
CA
Canada
Prior art keywords
alkyl
heterocycle
aryl
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2837207A
Other languages
English (en)
Inventor
Grayson B. Lipford
Charles M. Zepp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janus Biotherapeutics Inc
Original Assignee
Janus Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Biotherapeutics Inc filed Critical Janus Biotherapeutics Inc
Publication of CA2837207A1 publication Critical patent/CA2837207A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36Sulfur atom
    • C07D473/38Sulfur atom attached in position 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
CA2837207A 2011-06-01 2012-06-01 Nouveaux modulateurs du systeme immunitaire Abandoned CA2837207A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161491966P 2011-06-01 2011-06-01
US61/491,966 2011-06-01
PCT/US2012/040425 WO2012167053A1 (fr) 2011-06-01 2012-06-01 Nouveaux modulateurs du système immunitaire

Publications (1)

Publication Number Publication Date
CA2837207A1 true CA2837207A1 (fr) 2012-12-06

Family

ID=47259890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837207A Abandoned CA2837207A1 (fr) 2011-06-01 2012-06-01 Nouveaux modulateurs du systeme immunitaire

Country Status (6)

Country Link
US (1) US9353115B2 (fr)
EP (1) EP2713737B1 (fr)
AU (1) AU2012262021B2 (fr)
CA (1) CA2837207A1 (fr)
ES (1) ES2583877T3 (fr)
WO (1) WO2012167053A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE13857477T2 (hu) * 2012-11-20 2018-05-28 Glaxosmithkline Llc Új vegyületek
EP2953950B1 (fr) 2013-02-11 2021-01-13 The Regents of The University of California Compositions et méthodes de traitement de maladies neurodégénératives
HRP20220759T1 (hr) * 2014-02-11 2022-09-02 Mitokinin, Inc. Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
US11180474B2 (en) 2016-07-30 2021-11-23 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
ES2902504T3 (es) 2016-09-09 2022-03-28 Bristol Myers Squibb Co Compuestos de indol sustituidos con piridilo
CN108069960A (zh) * 2016-11-15 2018-05-25 江苏豪森药业集团有限公司 利奥西呱中间体的制备方法
KR20200019228A (ko) * 2017-06-21 2020-02-21 미토키닌, 인크. 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
WO2019028301A1 (fr) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company Composés d'indole substitués par [1,2,4]triazolo[4,3-a] pyridinyle
US11447466B2 (en) 2017-08-04 2022-09-20 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of TLR7/8/9
AU2018364807B2 (en) * 2017-11-08 2022-05-19 Council Of Scientific & Industrial Research Purine based compounds as toll-like receptor 9 antagonist
EP3710440B1 (fr) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Composés d'indole substitués
CA3085817A1 (fr) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company Composes de 4-azaindole
WO2019126113A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Composés d'indole substitués utiles en tant qu'inhibiteurs de tlr
EA202091483A1 (ru) 2017-12-19 2020-10-28 Бристол-Маерс Сквибб Компани Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
EP3728253B1 (fr) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company Composés de 6-azaindole
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
EA202091479A1 (ru) 2017-12-20 2020-11-24 Бристол-Маерс Сквибб Компани Арил- и гетероарилзамещенные индольные соединения
CN111491929B (zh) 2017-12-20 2023-11-28 百时美施贵宝公司 可用作tlr抑制剂的氨基吲哚化合物
TW202043234A (zh) 2019-01-24 2020-12-01 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
CA3226162A1 (fr) 2021-07-09 2023-01-12 Plexium, Inc. Composes aryle et compositions pharmaceutiques modulant l'ikzf2

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL86007A0 (en) 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
BR9407799A (pt) * 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
FI951367A (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2194761C (fr) 1994-07-15 2006-12-19 Arthur M. Krieg Oligonucleotides immunomodulateurs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
WO1998037919A1 (fr) 1997-02-28 1998-09-03 University Of Iowa Research Foundation UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
JP2002514083A (ja) 1997-05-07 2002-05-14 シェーリング コーポレイション ヒトToll様レセプタータンパク質、関連する試薬および方法
EP1003531B1 (fr) 1997-05-20 2007-08-22 Ottawa Health Research Institute Procedes de preparation de constructions d'acides nucleiques
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
AU3884199A (en) 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
EA200200424A1 (ru) * 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
AU3540101A (en) * 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
AU6488901A (en) 2000-05-25 2001-12-03 Schering Corp Human receptor proteins; related reagents and methods
SG177000A1 (en) 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
JP2005506350A (ja) * 2001-10-18 2005-03-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物
US20050227933A1 (en) * 2001-11-29 2005-10-13 Benkovic Stephen J Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
MX2011008500A (es) 2009-02-11 2011-09-26 Univ California Moduladores del receptor tipo toll y tratamiento de enfermedades.

Also Published As

Publication number Publication date
ES2583877T3 (es) 2016-09-22
AU2012262021B2 (en) 2016-07-28
EP2713737A4 (fr) 2014-11-26
EP2713737A1 (fr) 2014-04-09
WO2012167053A1 (fr) 2012-12-06
EP2713737B1 (fr) 2016-04-20
US20140107115A1 (en) 2014-04-17
US9353115B2 (en) 2016-05-31
AU2012262021A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
AU2012262021B2 (en) Novel immune system modulators
US10117875B2 (en) Immune system modulators
EP2763677B1 (fr) Nouveaux modulateurs du système immunitaire à base d'imidazole quinoline
US20170275287A1 (en) Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
KR20080108353A (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
JP2005516053A (ja) 縮合複素環式化合物
RU2198888C2 (ru) 3-замещенные производные 3,4,5,6,7,8-гексагидропиридо[4',3':4,5]-тиено[2,3-d]пиримидина
CA3097403A1 (fr) Inhibiteurs de stat3
CA2954231A1 (fr) Derives de quinolizinone utilises comme inhibiteurs de pi3k
KR102264189B1 (ko) Pi3k 억제제인 피라졸로피리미딘 화합물 및 이의 용도

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191105